نبذة مختصرة : Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Gastric cancer is the second leading cause of cancer-related death worldwide. the identification of new cancer biomarkers is necessary to reduce the mortality rates through the development of new screening assays and early diagnosis, as well as new target therapies. in this study, we performed a proteomic analysis of noncardia gastric neoplasias of individuals from Northern Brazil. the proteins were analyzed by two-dimensional electrophoresis and mass spectrometry. for the identification of differentially expressed proteins, we used statistical tests with bootstrapping resampling to control the type I error in the multiple comparison analyses. We identified 111 proteins involved in gastric carcinogenesis. the computational analysis revealed several proteins involved in the energy production processes and reinforced the Warburg effect in gastric cancer. ENO1 and HSPB1 expression were further evaluated. ENO1 was selected due to its role in aerobic glycolysis that may contribute to the Warburg effect. Although we observed two up-regulated spots of ENO1 in the proteomic analysis, the mean expression of ENO1 was reduced in gastric tumors by western blot. However, mean ENO1 expression seems to increase in more invasive tumors. This lack of correlation between proteomic and western blot analyses may be due to the presence of other ENO1 spots that present a slightly reduced expression, but with a high impact in the mean protein expression. in neoplasias, HSPB1 is induced by cellular stress to protect cells against apoptosis. in the present study, HSPB1 presented an elevated protein and mRNA expression in a subset of gastric cancer samples. However, no association was observed between HSPB1 expression and clinicopathological characteristics. Here, we identified several possible biomarkers of gastric cancer in individuals from Northern Brazil. These biomarkers may be useful for the assessment of prognosis and stratification for therapy if validated in larger clinical study sets. Universidade Federal de São Paulo, Div Genet, Dept Morphol & Genet, São Paulo, Brazil Universidade Federal de São Paulo, Dept Microbiol Immunol & Parasitol, São Paulo, Brazil Fed Univ Para, Joao de Barros Barreto Univ Hosp, Surg Serv, BR-66059 Belem, Para, Brazil Fed Univ Para, Joao de Barros Barreto Univ Hosp, Pathol Serv, BR-66059 Belem, Para, Brazil Universidade Federal de São Paulo, Dept Gynecol, São Paulo, Brazil Univ São Paulo, Sch Med, Expt Oncol Lab, São Paulo, Brazil Fed Univ Para, Human Cytogenet Lab, Inst Biol Sci, BR-66059 Belem, Para, Brazil Universidade Federal de São Paulo, Div Genet, Dept Morphol & Genet, São Paulo, Brazil Universidade Federal de São Paulo, Dept Microbiol Immunol & Parasitol, São Paulo, Brazil Universidade Federal de São Paulo, Dept Gynecol, São Paulo, Brazil Web of Science
No Comments.